Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 285.72M -4.0% |
| Revenue (ttm) | n/a |
| Net Income | -152.64M |
| EPS | -2.88 |
| Shares Out | 61.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,416,165 |
| Open | 5.080 |
| Previous Close | 5.160 |
| Day's Range | 4.495 - 5.080 |
| 52-Week Range | 4.495 - 13.670 |
| Beta | 2.13 |
| Analysts | Strong Buy |
| Price Target | 30.40 (+558.01%) |
| Est. Earnings | Nov 16, 2026 |
About KYTX
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KYTX stock is "Strong Buy." The 12-month stock price target is $30.4, which is an increase of 558.01% from the latest price.
News
Kyverna Therapeutics highlights updated clinical data with Miv-cel
Kyverna Therapeutics (KYTX) announced updated data from a Phase 1 investigator-initiated trial of miv-cel in patients with progressive multiple sclerosis. The data will be shared today in an oral pres...
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving dis...
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS ...
Kyverna Therapeutics Transcript: Study update
One-year data from the SPS trial show 95% of patients maintained significant mobility improvements and remained off immunotherapies, with similar durable, drug-free responses in gMG. Safety profile remains consistent and manageable, supporting outpatient use and a strong regulatory and commercial outlook.
Kyverna Therapeutics Press release: Study update
Kyverna Therapeutics issued a press release on September 24, 2026, disclosing material business information to investors.
Kyverna Therapeutics Slides: Study update
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Kyverna Therapeutics Slides: Investor presentation
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG
Kyverna Therapeutics (KYTX) announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel – mivocabtagene autoleucel, KYV-101 – in patients with stiff person syndrome or SP...
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel's differentiated construct
Kyverna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Transformative cell therapy miv-cel is advancing toward regulatory approval for Stiff Person Syndrome, with strong safety and efficacy data and a rolling BLA submission expected to complete in Q4. Expansion into gMG and progressive MS is underway, with pivotal trials and commercialization plans targeting rare disease populations.
Kyverna Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Cell therapy for autoimmune diseases is advancing rapidly, with miv-cel showing strong efficacy and safety in stiff person syndrome and myasthenia gravis. Regulatory progress, robust clinical data, and a focused commercialization strategy position the therapy for near-term launch and broader pipeline expansion.
Kyverna Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Transformative clinical results for miv-cel in SPS and MG drive regulatory progress, with a rolling BLA for SPS on track for Q4 completion and launch readiness in 2027. Manufacturing innovations and focused commercialization strategies support expansion into larger neuroimmunology indications.
Kyverna Therapeutics to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologi...
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
“Kyverna continues to advance our rolling BLA submission for stiff person syndrome, progress commercial launch readiness activities and accelerate enrollment in our registrational trial in generalized...
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunol...
Kyverna Therapeutics Earnings release: Q2 2026
Kyverna Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Kyverna Therapeutics Quarterly report: Q2 2026
Kyverna Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Kyverna Therapeutics Slides: Corporate presentation
Kyverna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
Kyverna Therapeutics (KYTX) and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, Kyverna’s autologous CD19-directed CAR T-cell therapy. Th...
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass.
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
Kyverna Therapeutics (KYTX) announced the appointment of Ritesh Srivastava as chief legal and compliance officer, effective June 22. Srivastava brings extensive experience spanning legal, corporate st...
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune ...
Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Pioneering autologous CAR T therapies, the company reported strong clinical results in SPS and MG, with no high-grade adverse events and significant functional improvements. FDA alignment and scalable manufacturing support a Q4 BLA submission and targeted commercial launch.